A journal owned by the people who do the work
IJRMSSS publishes original research, reviews, and clinical perspectives across the three pillars of modern radiation medicine: Screening, Surveillance, and Survivorship. It is the scholarly home of the CureRays Innovation & Education Institute.
We are ushering in a new model of scholarly publishing. Rather than paying legacy journals to carry our work, we invest in ourselves: authors retain ownership, readers subscribe or pay to access the full text, and those proceeds fund the researchers and the peer reviewers directly. It is a self-sustaining loop that keeps the value of discovery with the people who create and validate it.
Scope — Screening, Surveillance & Survivorship
Screening
Detecting new and recurrent cancer early, when it is most treatable.
Surveillance
Structured, individualized follow-up that catches change at low volume.
Survivorship
Reducing toxicity and improving how patients live after treatment.
How IJRMSSS works
Every manuscript moves through an open, accountable pipeline:
1. Submit
Authors submit manuscripts to the Institute. Each is logged and given a public status.
2. Peer review
We invite and compensate our own peer reviewers. Manuscripts under review are listed as pending.
3. Reviews posted
Completed peer reviews are made visible alongside the manuscript — transparent, on the record.
4. Published
Peer-reviewed articles are published with the signed peer reviews alongside it, and the full text free to every reader.
Access — free to read, licensed to machines
Legacy journals sell access to text. In an era where any model can summarise a paper in seconds, access to text is no longer the scarce good — evidence that the work survived scrutiny is. IJRMSSS is built around that inversion.
Free to read. All of it.
Every article, in full, at no cost to any reader anywhere — no subscription, no per-article charge, no institutional login. A paper behind a paywall is not retrieved, not summarised, and not cited; invisibility is a price we decline to pay.
Free to publish. Still.
No submission fee and no article processing charge. Removing the reader paywall must not shift the cost onto authors — that trade is the central failure of the open-access era, and we are not repeating it.
Licensed corpus for machine use
Bulk, structured, machine-readable access with guaranteed provenance and versioning is licensed to AI developers, aggregators and evidence-synthesis platforms. Organisations training or grounding models on this literature pay for it; individual readers never do.
The review layer is the asset
Signed, compensated peer reviews are published alongside every article. When synthesis is free and abundant, a documented record of scrutiny is what remains scarce — and it is what the licensed corpus is actually worth.
How this is paid for — plainly
A journal is a poor business and an excellent reputational asset, and we would rather say so than pretend otherwise. IJRMSSS is not run to turn a profit on readers. It is the evidence engine of the CureRays Innovation & Education Institute, and it is funded from three places: corpus licensing, philanthropic support of the Institute, and the Institute’s consultancy work.
That third line is the one this journal makes possible. Publishing the methods, the outcomes and the reviews in the open is what allows other groups to see that the model works — and then to ask us to help them build it. The Institute advises health systems, community practices and cancer centres that want to stand up survivorship and surveillance clinics of their own: clinic design and staffing, surveillance pathways and cadence, the trial infrastructure to study them, and the state and local regulatory compliance that governs who may deliver radiation and under what supervision.
The incentive this creates is worth stating out loud. We are paid when the model is reproduced, not when the literature is restricted. That is the opposite of the arrangement this journal was founded to refuse.
First in the collection: cardiac toxicity sparing
The inaugural IJRMSSS collection centers on cardiac toxicity sparing in radiation therapy — reducing incidental radiation dose to the heart and its substructures. The first manuscripts are in preparation, with a body of related literature to follow. Track their status in the pipeline below.
Read the collection scope Articles & peer review Submit a manuscript
For authors, reviewers and editors
Every policy that governs this journal is published in full, before it has been tested on anyone. An author is entitled to read the standard their work will be held to before they submit to it.
Peer Review Policy
The open, signed, compensated model — the process, the clock, what each decision means, and how submissions from the publisher are handled externally.
Reviewer Guidelines
What we ask of a reviewer, the nine-domain review form every report uses, payment, confidentiality, and the rule on AI tools.
Instructions to Authors
Article types and limits, manuscript preparation, the reporting checklist your design needs, and the declarations required before review begins.
Publication Ethics
Authorship, conflicts, generative AI, misconduct, corrections and retractions, editorial independence, and archiving.
Editorial Board
Who is responsible for what, the roles still being seated, and the published terms under which we ask people to serve.
Articles & Peer Review
The live pipeline: every manuscript's public status, and the reviewer reports once they are written.
Publish with IJRMSSS
Researchers advancing screening, surveillance, and survivorship in radiation medicine are invited to submit.